Form 4 for ANIX Anixa Biosciences Inc
Accepted 2024-10-23 00:00:00 ET · period of report 2024-10-22 · accession 0001493152-24-042183 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-10-23 | 2024-10-22 | ANIX | Titterton Lewis H jr | Dir | M - OptEx | $2.58 | +16.0K | 912.3K | +2% | +$41.3K |
| D | 2024-10-23 | 2024-10-22 | ANIX | Titterton Lewis H jr | Dir | M - OptEx | $0.00 | -16.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-22 | M | A | 16,000 | $2.58 | 912,334 | D | — | — | |
| 2 | Derivative | Employee Stock Option | 2024-10-22 | M | D | 16,000 | $0.00 | 0 | D | $2.58 · 2015-01-02 to 2025-01-02 | 16,000 Common Stock | (F1) Right-To-Buy, pursuant to a stock option grant dated January 2, 2015. |